Technological progress is often hindered by regulatory, economic, and structural bottlenecks rather than a lack of raw intelligence, challenging the prevailing belief that AGI will solve all societal problems.

Key Points

• Regulatory hurdles, such as the lengthy and costly clinical trial process, remain the primary obstacle to medical innovation rather than a lack of scientific capability.
• The current patent system incentivizes "target herding," where companies focus on de-risked biological targets rather than exploring new, high-risk medical frontiers.
• Economic data, such as Eroom’s Law, shows that R&D productivity has declined for decades despite significant advancements in scientific tools and AI capabilities.
• The San Francisco tech monoculture often prioritizes AGI development while ignoring systemic friction, such as housing shortages and the slow diffusion of technology into the real economy.
• Successful AI-driven biotech firms like Chai Discovery and Isomorphic Labs primarily focus on molecule optimization, which is a downstream task rather than a fundamental breakthrough in biological discovery.

Why it Matters

Overestimating the transformative power of AI while ignoring real-world governance and policy constraints leads to misaligned investment priorities and neglected societal issues. By focusing exclusively on "AGI-pilled" solutions, policymakers and investors risk failing to address the mundane but critical structural barriers that actually dictate the pace of human progress.